Assessment of Serum HSP20 Levels and Lipid Profile Alterations in Patients with Obesity and Cardiovascular Disease

Background: As a major risk factor for a number of cardiovascular illnesses (CVDs), such as hypertension and heart failure, obesity is a major global health concern. The purpose of this study was to examine the metabolic profiles and function of Heat Shock Protein 20 (HSP20) in patients with CVD and obesity. Methods: 43 people (aged 13 to 70) participated in a clinical trial at Nasiriya General Hospital. They were divided into three group: CVD patients (n=18), obese people (n=15), and healthy controls (n=10). Important bio marks were examined, such as blood glucose, lipid profile and HSP20. Results: The results showed that the obese group had a substantially higher BMI (31.17\0.92). LDL levels increased by 15.3% and HDL levels decreased by 12.7% in patients with CVD. On the other hand, those who were obese had triglyceride levels that were 18.5% higher. The prevalence of smoking among CVD patients was 57.7%, and both groups had elevated blood pressure and blood glucose. Notably, both obese and CVD participants had noticeably higher HSP20 levels. Conclusions: This study shows that a key risk factor for CVD in the participants is obesity induced metabolic dysregulation, which is marked by notable changes in lipid profiles and high blood glucose. The results show that these risks are much increased when smoking and hypertension coexist, which accelerates vascular problems. HSP20 is a crucial biomarker of physiological stress and a putative cardio protective mediator, as evidenced by the notable rise of serum HSP20 in both obese and CVD patients. Therefore, the best approach for reducing cardiovascular morbidity and using HSP20 for early diagnostic evaluation is still to treat obesity through integrated clinical and lifestyle therapies.